Alar Pharmaceuticals Inc.

Taipei Exchange 6785.TWO

Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) for the year ending December 31, 2023: 57,051,000

Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) is 57,051,000 for the year ending December 31, 2023, a 0.09% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.
  • Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) for the year ending December 31, 2022 was 57,000,000, a 0.00% change year over year.
  • Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) for the year ending December 31, 2021 was 57,000,000, a 14.21% change year over year.
  • Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) for the year ending December 31, 2020 was 49,907,000, a 42.59% change year over year.
  • Alar Pharmaceuticals Inc. Shares (Diluted, Weighted) for the year ending December 31, 2019 was 35,000,000.
Key data
Date Shares (Diluted, Weighted) Revenue Cost of Revenue Gross Profit
Market news
Taipei Exchange: 6785.TWO

Alar Pharmaceuticals Inc.

CEO Dr. Yung-Shun Wen Ph.D.
IPO Date Oct. 5, 2020
Location
Headquarters No. 32, Keya Road
Employees 22
Sector Health Care
Industries
Pharmaceuticals Clinical Trials
Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan. It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson's disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression. Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

StockViz Staff

January 15, 2025

Any question? Send us an email